E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Subjects with inadequately controlled, moderate to severe, chronic, cancer-related pain |
|
E.1.1.1 | Medical condition in easily understood language |
Pain, Burning
Pain, Crushing
Pain, Migratory
Pain, Radiating
Pain, Splitting |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10058019 |
E.1.2 | Term | Cancer pain |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the analgesic efficacy, safety, and tolerability of a single SC dose (9 mg in 0.9 mL) of JNJ-42160443 compared with placebo as adjunctive therapy to standard pain therapy in subjects with inadequately controlled, moderate to severe, chronic, cancer-related pain.
The primary efficacy objective of this study is to evaluate the analgesic effect of JNJ-42160443 compared with placebo, as measured by the change from baseline to the end of the double-blind treatment phase in the average cancer-related pain intensity score, using an 11-point numerical rating scale (NRS), with 0=no pain and 10=pain as bad as you can imagine. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to evaluate the efficacy of JNJ-42160443 compared with placebo, as measured by the Brief Pain Inventory (BPI) Short Form, Patient Global Impression of Change (PGIC), and baseline and breakthrough opioid use and to evaluate the immunogenicity (antibodies to JNJ-42160443) associated with JNJ-42160443 treatment, to examine the pharmacokinetics of JNJ-42160443.
Exploratory Objectives
The exploratory objectives of this study are to investigate the effects of improvements in pain relief with JNJ-42160443 on symptoms common in terminally ill subjects with cancer-related pain, including fatigue, sleep disturbance, emotional distress, aspects of daily activities, and anxiety/depression. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Terminally ill cancer patients as per judgment of the investigator (eg, subjects who are in or who are candidates for hospice or palliative care for end-of-life management.
• Diagnosis of moderate to severe pain directly related to an active cancer that is not controlled by standard pain treatments
• Receiving a stable dose of opioid pain medications for at least 1 week before screening
• If receiving nonopioid pain medications, must be at stable dose for 1 week before screening
• Have an average daily pain intensity score of >=4 averaged over the last 3 days before treatment assignment, >= 5 for the worst pain score during the last 3 days before randomization, and a minimum single score of average pain intensity must be >=2
|
|
E.4 | Principal exclusion criteria |
• Planned major surgical procedures during the double-blind treatment phase that may affect study outcomes.
• Prior treatment with any other investigational NGF inhibitor therapy
• Known allergies, hypersensitivity, or intolerance to JNJ-42160443 or its excipients, including mammalian cell-derived (ie, Chinese hamster ovary) products
• Enrolled in any investigational study within the previous 4 weeks or 5 half-lives of the investigational drug (whichever is longer), or are currently enrolled in another investigational study at the time of screening |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy evaluation is the average cancer-related pain intensity in the last 24 hours recorded daily in the diary during the double-blind treatment phase using an 11-point NRS, with 0=no pain and 10=pain as bad as you can imagine.
The primary efficacy endpoint is the change from baseline to the end of the double-blind treatment phase in the average cancer-related pain intensity score, averaged over the last 3 days before randomization and over the last 7 days of the double-blind treatment phase. The average cancer-related pain intensity score is based on the average pain in the last 24 hours item recorded daily in the diary. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline (average cancer-related pain intensity score over the last 3 days before randomization) to the end of Week 4 (average cancer-related pain intensity score over the last 7 days of the double-blind treatment phase) |
|
E.5.2 | Secondary end point(s) |
1 - Change in pain intensity and interference item scores of the BPI Short Form
2 - PGIC
3 - Change in "how much pain you have right now" scores
4 - Change in "pain at its worst in the past 24 hours"
5 - Change in total opioid use |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 - End of Week 4, Week 52, and Week 60 for pain intensity; End of Week 4 for BPI
2 - At Visits 4, 6, 8, 10
3 - End of Week 4, Week 52, and Week 60
4 - End of Week 4, Week 52, and Week 60
5 - End of Week 4 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Followed by an Open-Label Extension Phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 16 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Portugal |
Spain |
Poland |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 10 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 10 |